November 2024's Top Penny Stocks To Consider

In This Article:

As global markets show broad-based gains, with U.S. indexes nearing record highs and smaller-cap indexes outperforming, investors are increasingly looking for opportunities in less traditional areas of the market. Penny stocks, though an outdated term, continue to offer intriguing possibilities for those seeking growth at lower price points. These stocks often represent smaller or newer companies that can provide significant returns when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

DXN Holdings Bhd (KLSE:DXN)

MYR0.48

MYR2.39B

★★★★★★

Embark Early Education (ASX:EVO)

A$0.80

A$146.79M

★★★★☆☆

Lever Style (SEHK:1346)

HK$0.86

HK$545.92M

★★★★★★

LaserBond (ASX:LBL)

A$0.565

A$66.23M

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.89

MYR295.43M

★★★★★★

ME Group International (LSE:MEGP)

£2.22

£836.42M

★★★★★★

Next 15 Group (AIM:NFG)

£4.20

£417.71M

★★★★☆☆

Secure Trust Bank (LSE:STB)

£3.92

£74.76M

★★★★☆☆

United U-LI Corporation Berhad (KLSE:ULICORP)

MYR1.55

MYR337.59M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.79

A$231.32M

★★★★★★

Click here to see the full list of 5,755 stocks from our Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Nightingale Health Oyj

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nightingale Health Oyj is a health technology company that provides a health data platform for detecting disease risks across Finland, the United Kingdom, Europe, the United States, and internationally, with a market cap of €182.23 million.

Operations: The company generates revenue from its Medical Labs & Research segment, amounting to €4.36 million.

Market Cap: €182.23M

Nightingale Health Oyj, with a market cap of €182.23 million, is navigating the penny stock landscape with strategic moves such as its partnership with Boston Heart Diagnostics to expand its Health Check service in the U.S. Despite generating €4.36 million in revenue from its Medical Labs & Research segment, it remains unprofitable and is not expected to achieve profitability in the near term. The company has a solid cash runway exceeding three years and minimal debt, positioning it well for future growth opportunities. Recent executive appointments aim to bolster its strategic direction and global reach in health technology.

HLSE:HEALTH Financial Position Analysis as at Nov 2024
HLSE:HEALTH Financial Position Analysis as at Nov 2024

Golden Solar New Energy Technology Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆